GLP-1 agonist liraglutide decreases operant methamphetamine intake in rats under conditions of short- but not extended-access to the drug

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	HRICKOVÁ Mária DEMIRCI Sefa Furkan AMCHOVÁ Petra RUDÁ Jana
Year of publication	2026
Type	Peer-reviewed scientific article
Magazine / Source	Frontiers in Pharmacology
MU Faculty or unit	Faculty of Medicine
Citation
web	https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1791206/full
Doi	https://doi.org/10.3389/fphar.2026.1791206
Keywords	extended-access; GLP-1 agonist; intravenous self-administration; liraglutide; methamphetamine; rats
Description	GLP-1 receptor agonist liraglutide can reduce methamphetamine-taking behavior under conditions of low intake, whereas in the extended-access protocol, where drug intake escalates, the treatment shows no effect. Further research should better characterize its optimal dosing, duration of action, and brain penetration in rats.
Related projects:	Preclinical and clinical research at the Institute of Pharmacology: Pharmacokinetics, behavioral neuropsychopharmacology, and personalized pharmacotherapy